Floatz logo

Surufatinib

Angiogenesis

Fujian Cancer HospitalSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Angiogenesis cohort.

Asset / SponsorPhaseRating
Erythropoietin Human Recombinant
Ajou University School of Medicine
Phase 2BB
Carboplatin
Wenjun Cheng
Phase 3BB
Catequentinib
Wenjun Cheng
Phase 2BB
Endostar
Fujian Cancer Hospital
Phase 3B
Rivoceranib
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Phase 2CCC

View all 11 →

Same molecule, other indications

Surufatinib is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
neuroendocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →